
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc., an early clinical-stage biopharmaceutical company, is dedicated to developing innovative treatments for neurodegenerative diseases and psychiatric disorders, with a strong focus on its promising pipeline candidates AL001 and AL002. The company has recently reported positive top-line results from its studies, which are expected to serve as significant catalysts for future stock performance. Additionally, the current valuation is viewed as attractive, with substantial upside potential identified through a net present value analysis, reflecting a favorable outlook for the company's financial growth.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, resulting in an earnings per share (EPS) of $(1.28), significantly worse than the estimated EPS of $(0.69). The company faces multiple risks that could hinder its financial performance, including liquidity challenges and the potential failure of its drug candidates to prove safety and efficacy during clinical trials. Additionally, the competitive landscape and obstacles in commercialization and regulatory approval could further complicate the company’s ability to secure reimbursement and market its products effectively.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares